Nobody dares stopping clinical research, not even COVID-19

★

☆

SHARE

Overview

Paper Summary

Conflicts of Interest

Identified Weaknesses

Rating Explanation

Good to know

Topic Hierarchy

File Information

Paper Summary

Paperzilla title

How One Company Kept Clinical Trials Going During Early COVID-19 (Limited Scope)

This study describes how a single company adapted its clinical trial operations during the first nine months of the COVID-19 pandemic, implementing measures like remote monitoring and telehealth visits. The limited scope to one company and relatively short timeframe are major limitations, restricting the generalizability of the findings.

Possible Conflicts of Interest

Several authors are employed by MEDSIR, the company whose practices are the subject of the study. Additionally, several authors disclose financial ties to pharmaceutical companies.

Identified Weaknesses

The study focuses on a single company's experience.

This limits the generalizability of the findings and makes it difficult to draw broad conclusions about the impact of the pandemic on clinical trials.

The study only covers the first nine months of the pandemic.

The limited timeframe prevents the study from capturing the long-term impacts of the pandemic on clinical trials.

Lack of a control group

This is a descriptive study, not designed to test any specific hypothesis or establish causal relationships.

Reliance on self-reported data

This makes it difficult to quantitatively assess the impact of the adopted measures.

Rating Explanation

This is a descriptive study with limited generalizability, providing a snapshot of one company's experience. While it offers valuable insights into adaptations made during a challenging time, its scope and methodology prevent a higher rating. The disclosed conflicts of interest also contribute to the lower rating.

Good to know

This is our free standard analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.

Explore Pro →